EGFR and breast cancer: Upon FIP200 depletion, they found a decrease in the phosphorylation of EGFR, with this resulting in decreased STAT3 activation and consequently in an impairment of ALDH+ breast cancer stem cells (BCSCs) tumorigenicity.